Researchers say it’s a sign that more targeted therapies are needed for the vulnerable patient population.

The finding will indicate how aggressively physicians should treat patients with the associated condition.

Patients with obesity are especially at risk.

A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.

Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.

By studying the roles of an inflammatory protein and antibodies in chronic rejection after lung transplantation, researchers discover possibilities for new treatments.